Latest News on LAB

Financial News Based On Company


Advertisement
Advertisement

Standard BioTools (LAB) updates Treeline merger analyses ahead of November 19 vote.

https://www.stocktitan.net/sec-filings/LAB/8-k-standard-biotools-inc-reports-material-event-fc1e72ae86dc.html
Standard BioTools Inc. (LAB) has supplemented its proxy statement with updated financial analyses related to its proposed merger with Treeline Biosciences, ahead of a November 19, 2026 stockholder vote. Centerview's liquidation analysis estimated Standard BioTools' equity value at $468 million, or $1.14 per share, while Treeline's per-share valuation ranged from $15.88-$21.89 (Centerview) to $13.59-$17.07 (UBS). The company also addressed multiple demand letters and two New York complaints alleging omissions from merger voting materials, denying the claims but voluntarily providing supplemental disclosures.

A healthcare-only investment firm buys a business from Standard BioTools (LAB).

https://www.stocktitan.net/sec-filings/LAB/425-standard-biotools-inc-business-combination-communication-6cbb1cf088c6.html
Standard BioTools Inc. (LAB) announced on November 3, 2026, the completion of the sale of its Microfluidics business to ARCHIMED, a healthcare-focused investment firm. Concurrently, the company stated its definitive proxy statement/prospectus for a proposed transaction with Treeline Biosciences was declared effective on October 21, 2026, and mailed to stockholders. This Form 8-K filing confirms the closing of the Microfluidics divestiture, which was reported via a joint press release with ARCHIMED.

Form 4 Standard Biotools Inc: Thomas D. Carey (Director) For: 5 November By Investing.com

https://in.investing.com/news/stock-market-news/form-4-standard-biotools-inc-thomas-d-carey-director-for-5-november-93CH-5685370
This article reports on a Form 4 filing for Standard Biotools Inc, indicating a transaction by Director Thomas D. Carey on November 5. The article itself is very brief, serving primarily as an announcement of the filing rather than an in-depth analysis of the transaction details. It was published on November 6, 2026, according to the provided timestamp.

Form 4 Standard Biotools Inc: Thomas D. Carey (Director) For: 5 November

https://uk.investing.com/news/stock-market-news/form-4-standard-biotools-inc-thomas-d-carey-director-for-5-november-93CH-4963036
This article reports on a Form 4 filing for Standard Biotools Inc, indicating activity by director Thomas D. Carey on November 5th. The filing is a standard regulatory disclosure related to insider transactions.

Standard BioTools director Thomas Carey buys $46,897 in stock By Investing.com

https://ca.investing.com/news/stock-market-news/standard-biotools-director-thomas-carey-buys-46897-in-stock-93CH-4936918
Thomas D. Carey, a director at Standard BioTools Inc. (NASDAQ:LAB), recently purchased 75,000 shares of the company's common stock for $46,897 at a price of $0.6253 each. This transaction occurred on November 5, 2026, when the stock was trading near its 52-week low. Following this acquisition, Mr. Carey now directly holds 419,456 shares of Standard BioTools.
Advertisement

Director Thomas D. Carey buys Standard BioTools (LAB) shares at $0.6253 each.

https://www.stocktitan.net/sec-filings/LAB/form-4-standard-biotools-inc-insider-trading-activity-330d3eeb166b.html
Standard BioTools Inc. (LAB) director Thomas D. Carey purchased 75,000 shares of common stock at $0.6253 per share on November 5, 2026. This direct purchase increased his total holdings to 419,456 shares and was reported without a Rule 10b5-1 plan. The transaction was officially accepted by the SEC EDGAR system on November 5, 2026, at 05:36 PM EST.

Form 4 STANDARD BIOTOOLS INC. For: Nov 05 Filed by: Carey Thomas D.

https://www.streetinsider.com/SEC+Filings/Form+4+STANDARD+BIOTOOLS+INC.+For%3A+Nov+05+Filed+by%3A+Carey+Thomas+D./27301853.html
Thomas D. Carey, a Director at STANDARD BIOTOOLS INC. (LAB), filed a Form 4 indicating a transaction on November 5, 2026. Carey acquired 75,000 shares of common stock at a price of $0.6253 per share, increasing his direct beneficial ownership to 419,456 shares. This filing reports changes in beneficial ownership of securities as required by the Securities Exchange Act of 1934.

Ongoing operations lost $15M as Standard BioTools (LAB) posted a Q3 profit.

https://www.stocktitan.net/sec-filings/LAB/10-q-standard-biotools-inc-quarterly-earnings-report-bcfdc4c2859f.html
Standard BioTools (LAB) reported a net income of $13.483 million in Q3 2026, a significant improvement from a $34.687 million net loss in the prior year, primarily due to a $28.460 million income from discontinued operations. While continuing operations recorded a $14.977 million loss, the company's nine-month net income reached $113.793 million, bolstered by a $172.3 million pretax gain from the SomaScan sale. Standard BioTools is also progressing with its all-stock merger with Treeline Biosciences and is in the process of divesting its mass cytometry and microfluidics businesses.

Standard BioTools 3Q 2026: Revenue $19.4M, Net income $13.5M, EPS $0.03— 10-Q Summary

https://www.tradingview.com/news/tradingview:4d66d7cc0ae95:0-standard-biotools-3q-2026-revenue-19-4m-net-income-13-5m-eps-0-03-10-q-summary/
Standard BioTools reported its third-quarter 2026 financial results, with revenue of $19.4 million, a slight decrease from the prior year. The company achieved a net income of $13.5 million, a significant improvement from a net loss in the previous year, with diluted EPS of $0.03. These results were boosted by income from discontinued operations, and the company is proceeding with strategic asset sales and a merger with Treeline.

The team stays as Standard BioTools (LAB) sells its genomics tools business, which gets a new name.

https://www.stocktitan.net/sec-filings/LAB/8-k-standard-biotools-inc-reports-material-event-8f4d7abaf3ee.html
Standard BioTools Inc. (LAB) has completed the sale of its Microfluidics business to ARCHIMED, a healthcare-focused investment firm. The divested business will now operate as Biomark Scientific, maintaining its dedicated team and the Biomark platform, specializing in high-throughput and multi-assay genomics systems. This strategic move aims to expand Biomark Scientific's capabilities and support scientific discovery in genomics, clinical research, and public health.
Advertisement

ARCHIMED Life Science Tools & Services Completes Acquisition of Standard BioTools’ Microfluidics Business, Now Biomark Scientific

https://www.manilatimes.net/2026/11/03/tmt-newswire/globenewswire/archimed-life-science-tools-services-completes-acquisition-of-standard-biotools-microfluidics-business-now-biomark-scientific/2460550
Global private equity healthcare specialist ARCHIMED has completed its acquisition of Standard BioTools' Microfluidics Business, which will now operate independently as Biomark Scientific. Biomark Scientific specializes in high-throughput and multi-assay genomics systems, offering versatile and scalable genomic profiling through its Biomark™ platform, including the automated Biomark X9 system. This acquisition aims to expand Biomark Scientific's capabilities, fortify global growth in clinical research and public health markets, and support scientific discovery.

Form 8K Standard Biotools Inc For: 3 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-8k-standard-biotools-inc-for-3-november-93CH-4925628
This article reports on the filing of a Form 8K by Standard Biotools Inc. on November 3, 2026. The Form 8K is a crucial document that U.S. public companies must file with the SEC to announce significant events that shareholders should know about. This filing pertains to Standard Biotools Inc. and was published by Investing.com.

ARCHIMED Life Science Tools & Services Completes Acquisition of Standard BioTools’ Microfluidics Business, Now Biomark Scientific

https://finance.yahoo.com/healthcare/articles/archimed-life-science-tools-services-123000635.html
Global private equity healthcare specialist ARCHIMED has completed its acquisition of Standard BioTools' Microfluidics Business, which will now operate as Biomark Scientific. Biomark Scientific will continue to provide innovative microfluidics technology tools, specializing in high-throughput and multi-assay genomics systems, with plans to expand its capabilities in genomics, clinical research, and public health. This acquisition aims to fortify Biomark Scientific's global growth and establish it as a primary player in the industry, building on its established technology and customer relationships.

No resale proceeds will go to Standard BioTools (LAB) from Treeline holders’ merger shares.

https://www.stocktitan.net/sec-filings/LAB/424b3-standard-biotools-inc-prospectus-filed-pursuant-to-rule-424-b-3-cce8d40e9111.html
Standard BioTools Inc. (LAB) announced that it is registering up to 1.55 billion shares of common stock for resale by certain Treeline Biosciences, Inc. stockholders following their proposed all-stock merger. Standard BioTools will not receive any proceeds from these resales and will cover the registration costs, with selling holders bearing commissions. After the merger, former Treeline stockholders are expected to own approximately 84% of the combined company, and former Standard BioTools stockholders about 16%.

Standard BioTools Inc. Estimates – NASDAQ:LAB

https://www.tradingview.com/symbols/NASDAQ-LAB/financials-estimates/
This article provides an overview of Standard BioTools Inc. (NASDAQ: LAB) financial estimates on TradingView. It allows users to explore reported financial data and analyst estimates, comparing actual results with average, high, and low estimates across various financial statements and valuation metrics. The platform also visualizes trends over time for informed decision-making.
Advertisement

STANDARD BIOTOOLS INC. SEC Filing (Oct 22, 2026)

https://www.stocktitan.net/sec-filings/LAB/effect-standard-biotools-inc-sec-filing-e8350b1bffa3.html
This article reports on a Notice of Effectiveness filed by STANDARD BIOTOOLS INC. (NASDAQ: LAB) with the SEC on October 22, 2026. The filing, designated Form S-4, became effective on October 21, 2026, at 4:00 P.M. The article also provides a brief overview of the company's stock performance rankings, recent news, and other SEC filings.

Standard Biotools Inc (LAB-Q) Stock Price and News

https://www.theglobeandmail.com/investing/markets/stocks/LAB/
This article provides detailed stock information for Standard Biotools Inc (LAB-Q), including real-time stock price, daily performance metrics, and a comprehensive news feed from various financial sources. It highlights recent strategic decisions such as divestitures, merger agreements, and financial results, alongside the company's profile as a solution provider in health and disease using mass cytometry and microfluidics technologies.

Standard BioTools sells Microfluidics unit to ARCHIMED By Investing.com

https://ng.investing.com/news/stock-market-news/standard-biotools-sells-microfluidics-unit-to-archimed-93CH-2722365
Standard BioTools Inc. has announced a definitive agreement to sell its Microfluidics business to ARCHIMED, an investment firm specializing in healthcare. This transaction is anticipated to close in approximately 30 days, subject to standard closing conditions. This sale is part of Standard BioTools' broader strategic initiatives, which have included a merger with Treeline Biosciences and the sale of its Mass Cytometry business.

Standard BioTools sells Microfluidics unit to ARCHIMED By Investing.com

https://za.investing.com/news/stock-market-news/standard-biotools-sells-microfluidics-unit-to-archimed-93CH-4490662
Standard BioTools Inc. has announced the sale of its Microfluidics business to ARCHIMED, an investment firm specializing in healthcare industries. This transaction is another step in Standard BioTools' strategic actions, which include previous mergers and business sales. The financial terms were not disclosed, and the sale is expected to close within approximately 30 days, pending customary conditions.

Standard BioTools Announces Agreement to Sell Microfluidics Business to ARCHIMED

https://www.globenewswire.com/news-release/2026/10/05/3374997/0/en/standard-biotools-announces-agreement-to-sell-microfluidics-business-to-archimed.html
Standard BioTools Inc. announced its definitive agreement to sell its Microfluidics business to ARCHIMED, a healthcare investment firm. This transaction, expected to close in approximately 30 days, is part of Standard BioTools' strategic actions to streamline its business. Michael Egholm, CEO of Standard BioTools, highlighted ARCHIMED's expertise and resources as beneficial for the Microfluidics business's future growth and innovation.
Advertisement

Standard BioTools to Sell Microfluidics Business to Archimed

https://www.genomeweb.com/business-news/financial/mergers-acquisitions/gnw-standard-biotools-archimed-microfluidics-sale-20261005/
Standard BioTools has announced its intention to sell its microfluidics business to Archimed. The financial terms of the deal were not disclosed in this announcement. This transaction marks a strategic move for Standard BioTools.

Stocks to Watch: Standard BioTools, NeoGenomics, Pinterest

https://www.moomoo.com/news/post/1000624848/stocks-to-watch-standard-biotools-neogenomics-pinterest
This article highlights three stocks to watch: Standard BioTools (LAB), NeoGenomics (NEO), and Pinterest (PINS). Standard BioTools saw a significant price target increase from William Blair, while NeoGenomics received an upgrade from Bank of America. Pinterest is noted for positive analyst sentiment following its investor day.

Standard BioTools Announces Agreement to Sell Microfluidics Business to ARCHIMED

https://www.moomoo.com/news/post/1000619706/standard-biotools-announces-agreement-to-sell-microfluidics-business-to-archimed
Standard BioTools has announced an agreement to sell its microfluidics business to ARCHIMED for $100 million in cash. The transaction is expected to close in the fourth quarter of 2026 and will allow Standard BioTools to focus on its mass cytometry and imaging business.

Standard BioTools to Sell Microfluidics Business to ARCHIMED; Closing Expected in ~30 Days

https://www.tradingview.com/news/tradingview:1045e2ecfbeb7:0-standard-biotools-to-sell-microfluidics-business-to-archimed-closing-expected-in-30-days/
Standard BioTools (LAB) has entered into a definitive agreement to sell its Microfluidics business to ARCHIMED, a healthcare-focused investment firm. The transaction is anticipated to close in approximately 30 days, subject to standard closing conditions. This move is presented as a strategic action to benefit shareholders and potentially foster the growth of the business under new ownership.

Standard BioTools Announces Agreement to Sell Microfluidics Business to ARCHIMED

https://www.pmg-ky3.com/ap/ap_news/standard-biotools-announces-agreement-to-sell-microfluidics-business-to-archimed/article_9127a576-f342-5386-8add-3d7fdf30fd0f.html
Standard BioTools Inc. has announced a definitive agreement to sell its Microfluidics business to ARCHIMED, an investment firm focused on healthcare. This move is considered a strategic step for Standard BioTools, with CEO Michael Egholm stating that ARCHIMED's expertise will support the business's continued growth and innovation. The transaction is expected to close in approximately 30 days, subject to customary conditions.
Advertisement

Standard BioTools Announces Agreement to Sell Microfluidics Business to ARCHIMED

https://ca.finance.yahoo.com/news/standard-biotools-announces-agreement-sell-200500436.html
Standard BioTools Inc. announced its definitive agreement to sell its Microfluidics business to ARCHIMED, a healthcare-focused investment firm. The transaction is expected to close in approximately 30 days and is considered a strategic step for Standard BioTools. This move aims to allow the Microfluidics business to continue growing and innovating under ARCHIMED's ownership, leveraging their deep healthcare and life sciences expertise.

A healthcare-focused investor agrees to buy Microfluidics from Standard BioTools (LAB).

https://www.stocktitan.net/sec-filings/LAB/425-standard-biotools-inc-business-combination-communication-b651e4bc3c69.html
Standard BioTools Inc. has entered into a definitive agreement to sell its Microfluidics business to ARCHIMED, an investment firm specializing in healthcare. The transaction is anticipated to close in approximately 30 days, pending customary closing conditions. Risks to the completion of the sale include potential delays, unfulfilled conditions, termination events, and competing offers.

A conditional sale expected to close in about 30 days would move Microfluidics out of Standard BioTools (LAB).

https://www.stocktitan.net/sec-filings/LAB/8-k-standard-biotools-inc-reports-material-event-4286a809c502.html
Standard BioTools Inc. (LAB) has entered into a definitive agreement to sell its Microfluidics business to ARCHIMED, an investment firm specializing in healthcare. The transaction is anticipated to close in approximately 30 days, subject to standard closing conditions. This sale is considered another strategic step for Standard BioTools, with leadership believing it will allow Microfluidics to continue growth and innovation under new ownership.

Standard BioTools Inks New Agreement to Sell Mass Cytometry Business for $5.5M

https://www.genomeweb.com/business-news/financial/mergers-acquisitions/gnw-standard-biotools-new-mass-cytometry-deal-2061001/
Standard BioTools has entered into a new agreement to sell its mass cytometry business for $5.5 million. This transaction follows a previous attempt to sell the business that fell through. The sale aims to streamline the company's operations and focus on core strategic areas.

Form 4 Standard Biotools Inc For: 30 September By Investing.com

https://ng.investing.com/news/stock-market-news/form-4-standard-biotools-inc-for-30-september-93CH-2716862
This article announces the filing of a Form 4 for Standard Biotools Inc. for the period ending September 30. It's a brief financial news update from Investing.com, providing basic information about the SEC filing.
Advertisement

Form 4 Standard Biotools Inc For: 30 September By Investing.com

https://ca.investing.com/news/stock-market-news/form-4-standard-biotools-inc-for-30-september-93CH-4860917
The article reports on a Form 4 filing for Standard Biotools Inc. on September 30. It includes the company's stock performance and general market data from Investing.com. The content primarily serves as an announcement for the filing, with additional financial market information.

Standard BioTools switches Mass Cytometry buyer to Element for $5.5M

https://www.investing.com/news/company-news/standard-biotools-switches-mass-cytometry-buyer-to-element-for-55m-93CH-4925924
Standard BioTools Inc. (NASDAQ:LAB) has terminated its agreement with Multiplex Bio and entered a new definitive agreement to sell its Mass Cytometry Business to Element Biosystems, LLC for $5.5 million in cash. This change increases Standard BioTools' net cash position by approximately $15 million, as it removes the obligation for a $10 million working capital loan required in the previous deal. The transaction is expected to close by the end of 2026, concurrently with Standard BioTools’ merger with Treeline Biosciences.

Standard BioTools Finalizes $5.5M Mass Cytometry Business Sale to Element Biosystems

https://kalkinemedia.com/us/news/announcements/standard-biotools-finalizes-55m-mass-cytometry-business-sale-to-element-biosystems
Standard BioTools Inc. has terminated its prior agreement with Multiplex Bio Inc. to sell its mass cytometry division and instead entered a new $5.5 million cash deal with Element Biosystems, LLC. This change occurred after Standard BioTools received a "Business Superior Proposal" from GMT Venture Partners, Element Biosystems' parent company. The transaction is contingent on shareholder approval and the closing of Standard BioTools' merger with Treeline Biosciences, Inc.

Standard BioTools to Sell Mass Cytometry Business to Element Biosystems for $5.5 Million

https://www.tradingview.com/news/tradingview:2218c3d046240:0-standard-biotools-to-sell-mass-cytometry-business-to-element-biosystems-for-5-5-million/
Standard BioTools (LAB) has agreed to sell its mass cytometry business to Element Biosystems for $5.5 million in cash, supported by GMT Venture. This decision led to the termination of a prior agreement with Multiplex Bio, for which Standard BioTools will pay a $1.5 million fee, partially covered by GMT Venture. The new deal, which has no financing condition, is contingent on stockholder approval and the completion of Standard BioTools' merger with Treeline Biosciences.

Standard BioTools Provides Update on Sale of Mass Cytometry Business

https://www.globenewswire.com/de/news-release/2026/09/30/3372411/0/en/standard-biotools-provides-update-on-sale-of-mass-cytometry-business.html
Standard BioTools has terminated its agreement to sell its Mass Cytometry Business to Multiplex Bio and has entered into a new definitive agreement with Element Biosystems, LLC, an acquisition vehicle formed by GMT Venture Partners, for $5.5 million in cash. This change occurred after GMT Venture’s unsolicited proposal was deemed superior, leading to an increase in Standard BioTools' net cash position for its merger with Treeline Biosciences. The Element transaction is expected to close by the end of 2026, concurrently with the Treeline merger, pending stockholder approval.
Advertisement

Standard BioTools Announces Termination of Multiplex Bio Deal, Enters Agreement to Sell Mass Cytometry Business to Element Biosystems Ahead of Treeline Merger

https://www.quiverquant.com/news/Standard+BioTools+Announces+Termination+of+Multiplex+Bio+Deal%2C+Enters+Agreement+to+Sell+Mass+Cytometry+Business+to+Element+Biosystems+Ahead+of+Treeline+Merger
Standard BioTools Inc. has terminated its agreement with Multiplex Bio and instead entered into a definitive agreement to sell its Mass Cytometry Business to Element Biosystems, LLC for $5.5 million in cash. This new deal, spurred by an unsolicited proposal from GMT Venture Partners, is considered superior and will significantly enhance Standard BioTools' cash position by approximately $15 million. The transaction is expected to close by the end of 2026, concurrently with the company's merger with Treeline Biosciences, pending stockholder approval.

Standard BioTools Inc. - Common Stock (Nasdaq:LAB) Detailed Stock Data

https://markets.chroniclejournal.com/observerreporter/quote/detailedquote?Symbol=NQ%3ALAB
This article provides detailed stock data for Standard BioTools Inc. (Nasdaq:LAB), including its current price, trading metrics, and price performance over various periods. As of September 22, 2026, the stock was trading at $0.7498, unchanged, with a 52-week range of $0.6251 to $1.720. The company's shares outstanding are 378,860,686, and its Year-To-Date performance shows a significant decrease of 40.96%.

Standard BioTools (LAB) Short Interest & Short Float | Updated Sep 2026 $LAB

https://www.marketbeat.com/stocks/NASDAQ/LAB/short-interest/
Standard BioTools (LAB) saw an increase in short interest by 23.85% to 2.98 million shares as of August 31, 2026, representing 1.04% of its public float. The short interest ratio (days to cover) for LAB is currently 1.8, indicating it would take less than two days of average trading volume to cover all short positions. This article provides detailed historical short interest data and answers frequently asked questions about LAB's short interest metrics.

Protein Microarray Market Report Examines Industry Trends, Growth Drivers And Future Outlook

https://www.openpr.com/news/4613821/protein-microarray-market-report-examines-industry-trends
The protein microarray market is projected to reach $6.69 billion by 2030, growing at a CAGR of 9.2%, driven by advancements in personalized medicine, drug development, and biomarker discovery. Key players like PerkinElmer, Thermo Fisher Scientific, and Agilent Technologies are prominent, with innovations such as KREX technology and the i-ome discovery platform shaping its future. The market is segmented by type, technology, application, and end-user, reflecting its broad scope and evolving nature.

Standard BioTools (LAB) CFO sees stock withheld for taxes

https://www.stocktitan.net/sec-filings/LAB/form-4-standard-biotools-inc-insider-trading-activity-3228733220c0.html
Standard BioTools (LAB) CFO Hanjoon Alex Kim had 28,195 shares of common stock withheld on August 20, 2026, to cover tax withholding obligations from vested restricted stock units. This was a "code F" transaction, meaning the shares were withheld for tax payment rather than sold on the open market. After this transaction, Kim directly holds 2,534,859 shares of Standard BioTools common stock.
Advertisement

Standard BioTools (NASDAQ: LAB) exec uses 25.7K shares for taxes

https://www.stocktitan.net/sec-filings/LAB/form-4-standard-biotools-inc-insider-trading-activity-580364ba94ee.html
Sean Mackay, SVP & Chief Business Officer at Standard BioTools (NASDAQ: LAB), had 25,729 shares of common stock withheld on August 20, 2026, to cover tax obligations from vested restricted stock units. This transaction, valued at $0.672 per share, resulted in him holding 1,480,823 shares directly afterward. The event is a non-market disposition for tax purposes rather than a sale.

Enterprise value to EBIT forward of Standard BioTools Inc. – BX:FLB

https://www.tradingview.com/symbols/BX-FLB/financials-statistics-and-ratios/enterprise-value-ebit-fwd/
This article focuses on the enterprise value to EBIT forward for Standard BioTools Inc. (BX:FLB). It is presented as a financial data point within TradingView's platform, indicating that the content is likely a snippet from a financial analysis tool rather than an in-depth article. The text primarily consists of navigation and disclaimer information from the TradingView website.

Standard BioTools (LAB) holders report 7.3% stake in amended ownership filing

https://www.stocktitan.net/sec-filings/LAB/schedule-13g-a-standard-biotools-inc-amended-passive-investment-discl-18de4e3cc0aa.html
MAK Capital Fund LP, MAK Capital One LLC, and Michael A. Kaufman have filed an amended Schedule 13G, reporting a collective 7.3% ownership stake in Standard BioTools Inc. (LAB). This amounts to 28,813,904 shares of Common Stock, with shared voting and dispositive power among the reporting persons. The filing confirms their passive investment intent, not aimed at changing or influencing company control.

Standard BioTools (LAB): Long Focus Capital discloses 23.5M shares, 6% passive stake

https://www.stocktitan.net/sec-filings/LAB/schedule-13g-standard-biotools-inc-passive-investment-disclosure-5-85ab9f85ae19.html
Long Focus Capital Management, LLC and its controller, John Helmers, have disclosed a 6.0% passive stake in Standard BioTools Inc. (LAB), representing 23,500,000 shares of common stock as of June 30, 2026. This ownership is held on behalf of their clients, with shared voting and dispositive power, and no single client owns more than 5% of the outstanding common stock. The filing indicates a neutral sentiment and impact.

LAB: Standard BioTools Inc Latest Stock Price, Analysis, News and Trading Ideas

https://stocktwits.com/symbol/LAB.DL1023
This page provides a placeholder for information on Standard BioTools Inc. (LAB.DL1023), including its stock price, analysis, news, and trading ideas. It also features a sentiment indicator for the stock and links to general market discussions and polls related to the S&P 500 and Meta's earnings. The content indicates that news for LAB.DL1023 is still loading.
Advertisement

Standard BioTools (NasdaqGS:LAB) Stock Forecast & Analyst Predictions

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lab/standard-biotools/future
Standard BioTools (NasdaqGS:LAB) is facing a forecast decline in earnings by 5.8% annually, despite an expected annual revenue growth of 1.8%. The company recently withdrew its 2026 earnings guidance due to a pending merger with Treeline Biosciences and received a Nasdaq non-compliance notice for its share price falling below the minimum bid requirement. Analysts have adjusted price targets several times, reflecting volatility and ongoing strategic changes like divestitures and collaborations, while also noting significant shareholder dilution.

Standard BioTools (LAB) Stock Rebound Leaves Revenue Slide And Losses In Focus

https://www.sahmcapital.com/news/content/standard-biotools-lab-stock-rebound-leaves-revenue-slide-and-losses-in-focus-2026-08-07
Standard BioTools (LAB) saw a slight stock rebound after its Q2 2026 earnings, but this is overshadowed by a 7.6% revenue decline to US$20.1 million and persistent losses, despite a narrower net loss from continuing operations. The market is waiting for sustained top-line growth to justify its valuation, with both bullish and bearish arguments focusing on the company's ability to leverage mergers and partnerships against ongoing demand and funding challenges.

Standard BioTools Reports Second Quarter 2026 Financial Results

https://investingnews.com/standard-biotools-reports-second-quarter-2026-financial-results/
Standard BioTools Inc. announced its financial results for the second quarter of 2026, reporting $20.1 million in revenue and an 84% improvement in adjusted EBITDA year-over-year. The company is progressing with its merger with Treeline Biosciences, anticipated to close before year-end 2026, and has withdrawn its full-year 2026 revenue outlook due to this pending merger. The results also highlighted improved gross margins driven by productivity enhancements and cost discipline.

Standard BioTools Inc. (LAB) Stock Price, News, Quote & History

https://ca.finance.yahoo.com/quote/LAB/
This article provides comprehensive financial information for Standard BioTools Inc. (LAB), including its current stock price, historical data, and analyst ratings. It details the company's overview, its segments in proteomics and genomics, key products like the SomaScan platform and CyTOF technology, and financial performance metrics. The article also includes comparisons with similar medical device companies and recent news regarding analyst actions.

STANDARD BIOTOOLS INC. Q2 2026: Revenue $20.1M, EPS $(0.07) — 10-Q Summary

https://www.tradingview.com/news/tradingview:074a237963db1:0-standard-biotools-inc-q2-2026-revenue-20-1m-eps-0-07-10-q-summary/
STANDARD BIOTOOLS INC. reported its Q2 2026 results, showing revenue of $20.1M and a diluted loss per share of $(0.07), which indicates an improvement compared to the previous year. Key highlights include an announced merger with Treeline Biosciences, the divestiture of the SomaScan business to Illumina for $388.2M, and significant operational restructuring to reduce costs. The company also saw a decline in total revenue year-over-year but an increase in year-to-date consumables sales.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement